Literature DB >> 23859014

Research on DNA methylation of human osteosarcoma cell MGMT and its relationship with cell resistance to alkylating agents.

Jun Guo1, Qiu Cui, WeiHao Jiang, Cheng Liu, DingFeng Li, Yanjun Zeng.   

Abstract

The objective of this study was to explore the O(6)-methylguanine-DNA methyltransferase (MGMT) gene methylation status and its protein expression, as well as the effects of demethylating agent 5-Aza-2'-deoxycytidine (5-Aza-CdR) on MGMT gene expression and its resistance to alkylating agents, and to elucidate MGMT expression mechanism and significance in osteosarcoma. The human osteosarcoma cell lines Saos-2 and MG-63 were collected and treated with 5-Aza-CdR for 6 days. The cells not treated with 5-Aza-CdR were set as a negative control. The genomic DNA was extracted from the Saos-2 and MG-63 cells using methylation-specific PCR to detect the promoter CpG island methylation status of the MGMT gene. Cell sensitivity to alkylating agents before and after drug administration was detected by the MTT method. The variation in MGMT gene mRNA and protein was detected by reverse transcription PCR (RT-PCR) and Western blotting. The MGMT promoter gene of normal Saos-2 cells was methylated, with reduced MGMT mRNA and protein expression; the MGMT mRNA and protein expression of Saos-2 cells treated with 5-Aza-CdR was obviously enhanced, and its sensitivity to alkylating agents was reversed. Meanwhile, with promoter CpG island unmethylation of the MGMT gene, MGMT protein was expressed in the normal MG-63 cells and the MG-63 cells treated with 5-Aza-CdR, and both showed resistance to alkylating agents. The methylation status of the MGMT gene promoter in human osteosarcoma cells reflected the cells' ability to induce MGMT protein expression and can be used as a molecular marker to project the sensitivity of cancer tissues to alkylating agent drugs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23859014     DOI: 10.1139/bcb-2012-0100

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  5 in total

1.  Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor.

Authors:  Ryoichi Iwata; Masato Maruyama; Tomoki Ito; Yosuke Nakano; Yonehiro Kanemura; Taro Koike; Souichi Oe; Kunikazu Yoshimura; Masahiro Nonaka; Shosaku Nomura; Tetsuo Sugimoto; Hisao Yamada; Akio Asai
Journal:  Med Mol Morphol       Date:  2017-05-17       Impact factor: 2.309

Review 2.  Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.

Authors:  Guan Jiang; Ai-Jun Jiang; Yong Xin; Lian-Tao Li; Qian Cheng; Jun-Nian Zheng
Journal:  Mol Biol Rep       Date:  2014-07-03       Impact factor: 2.316

3.  LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway.

Authors:  Peng Du; Haiting Zhao; Renjun Peng; Qing Liu; Jian Yuan; Gang Peng; Yiwei Liao
Journal:  Biosci Rep       Date:  2017-09-07       Impact factor: 3.840

4.  Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.

Authors:  Gloria Perazzoli; Jose Prados; Raul Ortiz; Octavio Caba; Laura Cabeza; Maria Berdasco; Beatriz Gónzalez; Consolación Melguizo
Journal:  PLoS One       Date:  2015-10-08       Impact factor: 3.240

5.  miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely.

Authors:  Songhua Xiao; Zhen Yang; Xingsheng Qiu; Ruiyan Lv; Jun Liu; Ming Wu; Yiwei Liao; Qing Liu
Journal:  Oncotarget       Date:  2016-08-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.